4Langaee TY, Gagnon L, Huletsky A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob Agents Chemother, 2000, 44(3): 583-589.
5Giakkoupi P, Petrikkos G, Tzouvelekis LS, et al. Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol, 2003, 41(2): 822-825.
6Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother, 1998, 42(8): 2006-
7Akasaka T, Tanaka M, Yamaguchi A, et al. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents
8Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell, 1997, 88(6): 823-832.
9Mouneimne H, Robert J, Jarlier V, et al. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1999, 43(1): 62-66.
10Ochs MM, McCusker MP, Bains M, et al. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother, 1999, 43(5): 1085-1090.
